Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Interesting perspective
View:
Post by DJDawg on Dec 14, 2021 12:26pm

Interesting perspective

Hi
I had mentioned this company to a friend, whose husband is a type A kind of research person and it was interesting hear his perspective.

His concerns were as follows:
- penny stock price that his highly volatile in price.
- a glass door employee rating from 2017 that mentioned a dysfunctional workplace where the husband and wife owners have loud disagreements all the time. And who micromanage everything without realizing that they don't know everything.
- rapid CEO changeover (2 in the past 6 months alone)
- analyst ratings as a "speculative" play

He said it seems like a terrible idea to invest.

I found it fascinating as I completely agree. Everything I've read sounds like the leadership issues are big. It is speculative to a degree. The CEO changeover issues don't inspire faith at all.

I guess my only personal faith is that no matter how badly run the company is, if they are recruiting patients via the supporting centres, giving them the drug at a good dose and procedure at a good dose, that is what counts. Thankfully we are not relying on RDW's word regarding the medical results as those are controlled by the academic urologists rather than the corporate leadership. I have faith in some of the names on the med adv board and have faith in Vera and her background.

But overall, I can totally see why so many people will stay away a bit longer. Need the BTD to breakout I think.

Just in interesing perspective from my friend's husband. Thought I would share.

DJ
Comment by floatinketucky on Dec 14, 2021 12:41pm
And did what did they conclude of the science? Like the CR rates? The BTD?  Like the phase 2 trial being PIVITOL? The actual buisness/SCIENCE of the company?
Comment by menoalittle on Dec 14, 2021 12:43pm
>> The actual buisness/SCIENCE of the company? In short, it's simply not understood well enough to be believable to most people.
Comment by floatinketucky on Dec 14, 2021 12:45pm
Like who cares about the paint job, Can the vehicle get to the next buisness goal? The science seems clearly to be showing it very very likely. I thinik this is a good truck. 
Comment by DJDawg on Dec 14, 2021 12:55pm
Hey I'm with you guys. But I'm just pointing out that there is a mass of investors that are not getting to this stock (yet) because it has issues, hopefully more in the past. Even reading the CR results is confusing because there is optimized and non-optimized because they messed up and underdosed a bunch of patients AND removed them from the trial prematurely. The plus side is that if ...more  
Comment by fredgoodwinson on Dec 14, 2021 1:34pm
Here primarily for what x-ray activated Rutherrin may do against deep cancers but in addition to NMIBC there are many superficial cancers with less than satisfactory outcomes for which TLD-1433 may prove suitable.   Difficult to reconcile the thin-ness of the buy side at these modest levels with the Clinical data from the last Newsletter but continue to add.  
Comment by menoalittle on Dec 14, 2021 1:46pm
>> Difficult to reconcile the thin-ness of the buy side at these modest levels  it's because everything between 20 and 35 cents has already vacuumed up. only mere tidbits remain... (until the next 15 cent step up.) 
Comment by robertshaw on Dec 14, 2021 1:57pm
count on blowjobjoe's bosses selling more cheapies...
Comment by menoalittle on Dec 14, 2021 2:18pm
>> count on blowjobjoe's bosses selling more cheapies... well... what are they waiting for? Christmas ?
Comment by robertshaw on Dec 15, 2021 12:22pm
Here comes the Blowjobjoe's bosses' dumping as we expected.., But I guess less long shareholders dare to buy now as brave guys like Lesalpes29 and Sunvalley just did...
Comment by floatinketucky on Dec 15, 2021 12:55pm
If the stock maintains a quarter or so by the next release...
Comment by fredgoodwinson on Dec 14, 2021 2:28pm
TBH with the way they twist the market find that less surprising than there being only 1500 on the bid at 33.5,
Comment by menoalittle on Dec 14, 2021 2:34pm
ya, well... try not to be fooled by that wee little (iceberg's) size. I've seen 'em able to swallow a river.  
Comment by VerusSemperSors on Dec 14, 2021 4:41pm
It is a volatile, speculative, clinical-stage penny stock with periodic management conflicts. They do seem to have the goods. And management conflicts affect companies of all sizes. There's not enough total value for professional advisors to recommend it to their clients. Many of the retail investors that might stumble upon it on their own would not consider buying a speculative penny stock. ...more  
Comment by floatinketucky on Dec 14, 2021 5:11pm
I expect a move to .50 cents+ will be brought on more by price discovry individual investers  rather than professionaly advised investers. 
Comment by menoalittle on Dec 14, 2021 6:17pm
>> I expect a move to .50 cents+ will be brought on more by price discovry individual investers  rather than professionaly advised investers. more than professionally advised? okay, sure. there's always a few that stumble upon it. however, I surmise that the next step up will be primarily driven by the deep pockets of those already "in the know," as they continue to ...more  
Comment by floatinketucky on Dec 15, 2021 8:08am
Let's talk Dec 2nd buying. TLTFF action consisted of 626,028 shares sold that day with 408,197 shorted. Dec 2nd opened at .2066 and closed at .2592. I think the principal buying came from let's say Data aware private investors, who expect in the near term the stock price will rise. So they wanted to get them shares.   Let's talk Dec 3. TLTFF action consisted of 1,038,430 ...more  
Comment by Galaxym31 on Dec 14, 2021 10:08pm
Aggresive bashing B + .
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250